6 results on '"Makay, Balahan"'
Search Results
2. Inflammatory comorbidities ın the largest pediatric Familial Mediterranean fever cohort: a multicenter retrospective study of Pediatric Rheumatology Academy (PeRA)-Research Group (RG).
- Author
-
Ozdel, Semanur, Coşkuner, Taner, Demirkan, Fatmagül, Torun, Rüya, Aydın, Elif Arslanoglu, Bağlan, Esra, Yener, Gülçin Otar, Öztürk, Kübra, Demir, Ferhat, Karadağ, Şerife Gül, Çakan, Mustafa, Sönmez, Hafize Emine, Makay, Balahan Bora, Ünsal, Şevket Erbil, Bülbül, Mehmet, Ayaz, Nuray Aktay, and Sözeri, Betül
- Subjects
FAMILIAL Mediterranean fever ,PEDIATRIC rheumatology ,JUVENILE idiopathic arthritis ,CHILD patients ,COMORBIDITY ,CHEST pain ,CLUSTER headache - Abstract
Aim: The aim of this study was to investigate the frequency and type of FMF-associated inflammatory diseases in a large FMF pediatric patients and to compare them to those FMF patients without concomitant inflammatory diseases. Materials and methods: Familial Mediterranean fever patients enrolled in the Pediatric Rheumatology Academy (PeRA)-Research Group (RG) were included. The patients were divided into two groups according to concomitant inflammatory disease as FMF patients who had a concomitant inflammatory disease (group 1) and FMF patients who did not have a concomitant inflammatory disease (group 1). The clinical findings and treatments were compared between the two groups. Results: The study group comprised 3475 patients with FMF. There were 294 patients (8.5%) in group 1 and 3181 patients (91.5%) in group 2. Juvenile idiopathic arthritis (n = 136) was the most common accompanying inflammatory disease. Arthritis, M694V homozygosity, and the need for biological therapy were more frequently observed in Group 1 (p < 0.05). Fever and abdominal pain were more frequently detected in Group 2 (p < 0.05). FMF patients with concomitant inflammatory diseas more frequently demonstrated colchicine resistance. There were no significant differences in the median attack frequency, chest pain, amyloidosis, erysipelas-like erythema, or family history of FMF between the two patient groups. Conclusion: To the best of our knowledge, this is the largest pediatric cohort reviewed to date. FMF patients may have different clinical profiles and colchicine responses if they have with concomitant inflammatory diseases. Key points • FMF is associated with some inflammatory comorbidities diseases. • To the best of our knowledge, this is the largest cohort evlauated pediatric FMF associated inflammatory comorbidities diseases reviewed to date [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Remission rates and risk factors for relapse in pediatric morphea: a multicenter retrospective study of Pediatric Rheumatology Academy (PeRA)-Research Group (RG).
- Author
-
Bağlan, Esra, Kızıldağ, Zehra, Çağlayan, Şengül, Çakmak, Figen, Yener, Gülçin Otar, Özdel, Semanur, Öztürk, Kübra, Makay, Balahan, Çakan, Mustafa, Ayaz, Nuray Aktay, Sözeri, Betül, Ünsal, Şevket Erbil, and Bülbül, Mehmet
- Subjects
PEDIATRIC rheumatology ,SCLERODERMA (Disease) ,ANTINUCLEAR factors ,DISEASE relapse ,IMMUNOSUPPRESSIVE agents ,RETROSPECTIVE studies - Abstract
Aim: Morphea, also known as localized scleroderma, is an immune-mediated disease and the most common form of scleroderma in children. It is a localized sclerosing disease of the skin, but can also involve such adjacent tissues as the fascia, muscle, bone, and underlying tissues. This multicenter study aimed to evaluate Turkish pediatric morphea patients, regarding demographics, treatments, and response to treatment. Materials and methods: The study was performed by the Pediatric Rheumatology Academy and included pediatric morphea patients from 6 Turkish pediatric rheumatology centers who were followed up for ≥6 months. Demographic, clinical, and laboratory findings and treatment modalities were analyzed. The patients were divided into 3 groups according to treatment response, as follows: group 1: topical treatment response, group 2: methotrexate response, and group 3: methotrexate resistance. Clinical findings were compared between the 3 groups. Results: The study included 76 patients, of which 53 (69.7%) were female. Mean age at diagnosis of morphea was 9.7 ± 4.3 years and mean duration of follow-up was 3.2 ± 2.9 years. Linear morphea was the most common form, accounting for 43.4% (n = 33) of the patients. Extracutaneous features were noted in 17 patients (22.4%) and anti-nuclear antibody positivity was noted in 32 (42.1%). In all, 14.4% of the patients received topical treatment only, whereas 86.6% received both topical and systemic treatment. The methotrexate response rate was 76.9% in the patients that received systemic immunosuppressive therapy. The overall relapse rate while under treatment was 19.7%. Conclusion: In this study, most of the pediatric morphea patients responded well to methotrexate. Bilateral lesions were more common in the methotrexate-resistant group. Multiple involvement, and bilateral lesions, were more common in relapsed patients than in non-relapsed patients. Key points • Most of the pediatric morphea patients respond well to MTX. • Multiple involvement, and bilateral involvement, were more common in relapsed patients than in non-relapsed patients. • Presence of extracutaneous findings in patients increased relapse rate 5.7 times. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Clinical characteristics and predictors for recurrence in chronic nonbacterial osteomyelitis: a retrospective multicenter analysis.
- Author
-
ULU, Kadir, İŞGÜDER, Rana, KARADAĞ, Şerife Gül, BAĞLAN, Esra, KAVRUL KAYAALP, Gülşah, OTAR YENER, Gülçin, ÖZTÜRK, Kübra, SÖNMEZ, Hafize Emine, ÖZDEL, Semanur, DEMİR, Ferhat, MAKAY, Balahan, ÜNSAL, Şevket Erbil, SÖZERİ, Betül, AKTAY AYAZ, Nuray, and ÇAKAN, Mustafa
- Subjects
NONSTEROIDAL anti-inflammatory agents ,BLOOD sedimentation ,OSTEOMYELITIS ,DELAYED diagnosis ,CHILD patients ,PEDIATRIC rheumatology - Abstract
Background/aim: Chronic nonbacterial osteomyelitis (CNO) is a rare disease of unknown etiology and most commonly occurs during childhood or adolescence. The purpose of this study is to collect data on the clinical features, outcomes, and management of the disease and to identify the factors affecting recurrence. Materials and methods: This is a retrospective multicenter cross-sectional study of pediatric patients diagnosed with CNO. A total of 87 patients with a diagnosis of CNO followed for at least 6 months in 8 pediatric rheumatology centers across the country between January 2010 and December 2021 were included in this study. Results: The study included 87 patients (38 girls, 49 boys; median age: 12.5 years). The median follow-up time was 20 months (IQR: 8.5-40). The median time of diagnostic delay was 9.9 months (IQR: 3-24). Arthralgia and bone pain were the most common presenting symptoms. Multifocal involvement was detected in 86.2% of the cases and a recurrent course was reported in one-third of those included in the study. The most commonly involved bones were the femur and tibia. Vertebrae and clavicles were affected in 19.5% and 20.6% of cases, respectively. The erythrocyte sedimentation rate (ESR) values of 60.9% of the patients were above 20 mm/h and the C-reactive protein values of 44.8% were above 5 mg/L. The remission rate was 13.3% in patients using nonsteroidal antiinflammatory drugs and 75.0% in those using biological drugs. Vertebral and mandibular involvement and high ESR values at the time of diagnosis were associated with recurrence. Conclusion: In this multicenter study, CNO with vertebral and mandibular involvement and high ESR at diagnosis were associated with recurrence. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. How common is remission in rheumatoid factor-positive juvenile idiopathic arthritis patients? The multicenter Pediatric Rheumatology Academy (PeRA) research group experience.
- Author
-
Ozdel, Semanur, Sönmez, Hafize Emine, Çağlayan, Şengül, Akgün, Özlem, Aydın, Tuncay, Baba, Özge, Bağrul, İlknur, Yener, Gülçin Otar, Öztürk, Kübra, Demir, Ferhat, Yıldırım, Deniz Gezgin, Karadağ, Şerife Gül, Bağlan, Esra, Çakan, Mustafa, Kalyoncu, Mukaddes, Makay, Balahan Bora, Ünsal, Şevket Erbil, Bakkaloğlu, Sevcan, Bülbül, Mehmet, and Sözeri, Betül
- Subjects
JUVENILE idiopathic arthritis ,PEDIATRIC rheumatology ,FINGER joint ,RHEUMATOID factor ,RESEARCH teams ,MACROPHAGE activation syndrome ,DISEASE remission - Abstract
Objective: Rheumatoid factor (RF)-positive polyarthritis is the least common type of juvenile idiopathic arthritis (JIA). Functional disability in RF-positive polyarthritis patients is much more severe than in patients with other subtypes; but data on this subtype alone is limited. This study aimed to analyze clinical features, long-term follow-up, treatment response, and remission status in a large multicenter cohort of RF-positive polyarthritis patients. Methods: This retrospective study included RF-positive polyarthritis patients that were followed up for ≥ 6 months between 2017 and 2022 by the Pediatric Rheumatology Academy (PeRA)-Research Group (RG). Data on patient demographics, clinical and laboratory characteristics were obtained from medical charts. JIA treatments and duration of treatment were also recorded. The patients were divided into 2 groups based on methotrexate (MTX) response, as follows: group 1: MTX responsive, group 2: MTX unresponsive. Clinical and laboratory findings were compared between the 2 groups. Results: The study included 56 (45 female and 11 male) patients. The median age at onset of RF-positive polyarthritis was 13.2 years [(interquartile range) (IQR): 9.0–15.0 years] and the median duration of follow-up was 41.5 months (IQR: 19.5–75.7 months). Symmetrical arthritis affecting the metacarpophalangeal and proximal interphalangeal joints of the hands was commonly observed. Subcutaneous MTX was the preferred initial treatment; however, it was ineffective in 39 (69.6%) of the patients. Of 25 patients followed for 24 months, 56% still had active disease at 24 months. Conclusion: During 2 years of treatment, 44% of RF-positive polyarthritis patients have inactive disease, and they should be considered as a distinct and important clinical entity requiring aggressive and early treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. The Publication Rates of Pediatric Rheumatology Abstracts Presented in European League Against Rheumatism 2009 Congress.
- Author
-
GÜCENMEZ, Özge Altug, BAYRAKTAR, Deniz, KOÇAK, Umut Ziya, MAKAY, Balahan, and ÜNSAL, Şevket Erbil
- Abstract
Objectives: This study aims to evaluate the publication rates and features of the abstracts related to pediatric rheumatology presented in European League Against Rheumatism 2009 congress. Methods: A systematic search was performed to find full-text publications of abstracts related to pediatric rheumatology in European League against Rheumatism 2009 congress. Full-text publication rate, the elapsed time between presentation and full-text publication, type of thé disease In the studies, distribution of abstracts and full-texts according to countries, journals, and presentation types were investigated. Results: Totally 220 abstracts were detected related to pediatric rheumatology. Twenty-two of them had only the title, authors' names, and institution of origin, but no abstract. Therefore, a total number of 198 abstracts were evaluated. Eighty-six (43.4%) abstracts were found to be accepted as full-text articles. The elapsed time between presentation and full text publication was median 19 months (range 0 to 64 months). While 12 orally presented abstracts (34%) became full-text articles, this rate was 45% (74 abstracts) for poster presentations. There was no significant difference in the elapsed time to reach full-text publication and impact factors between presentation types (p=0.832 and p=0.053, respectively). Conclusion: The full-text publication rates were within similar ranges when compared to other reports in rheumatology field. It seems that even though European League against Rheumatism is a general rheumatology congress, it takes an important place in pediatric rheumatology field as well. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.